These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

526 related items for PubMed ID: 35803613

  • 21. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
    Laborda E, Mazagova M, Shao S, Wang X, Quirino H, Woods AK, Hampton EN, Rodgers DT, Kim CH, Schultz PG, Young TS.
    Int J Mol Sci; 2017 Oct 27; 18(11):. PubMed ID: 29077054
    [Abstract] [Full Text] [Related]

  • 22. Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia.
    Sánchez Martínez D, Tirado N, Mensurado S, Martínez-Moreno A, Romecín P, Gutiérrez Agüera F, Correia DV, Silva-Santos B, Menéndez P.
    J Immunother Cancer; 2022 Sep 27; 10(9):. PubMed ID: 36162920
    [Abstract] [Full Text] [Related]

  • 23. Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML).
    Lu Y, Liu Y, Wen S, Kuang N, Zhang X, Li J, Wang F.
    J Transl Med; 2022 Dec 14; 20(1):600. PubMed ID: 36517851
    [Abstract] [Full Text] [Related]

  • 24. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
    Li S, Tao Z, Xu Y, Liu J, An N, Wang Y, Xing H, Tian Z, Tang K, Liao X, Rao Q, Wang M, Wang J.
    Hum Gene Ther; 2018 May 14; 29(5):626-639. PubMed ID: 29409351
    [Abstract] [Full Text] [Related]

  • 25. CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia.
    Caulier B, Joaquina S, Gelebart P, Dowling TH, Kaveh F, Thomas M, Tandaric L, Wernhoff P, Katyayini NU, Wogsland C, Gjerstad ME, Fløisand Y, Kvalheim G, Marr C, Kobold S, Enserink JM, Gjertsen BT, McCormack E, Inderberg EM, Wälchli S.
    Cell Rep Med; 2024 Jun 18; 5(6):101572. PubMed ID: 38754420
    [Abstract] [Full Text] [Related]

  • 26. Chimeric antigen receptor T cells for acute myeloid leukemia.
    Fetsch V, Zeiser R.
    Eur J Haematol; 2024 Jan 18; 112(1):28-35. PubMed ID: 37455578
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells.
    Chen N, Xu Y, Mou J, Rao Q, Xing H, Tian Z, Tang K, Wang M, Wang J.
    Blood Cancer J; 2021 Aug 14; 11(8):144. PubMed ID: 34392305
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Construction of a new anti-CD123 chimeric antigen receptor T cells and effect of anti-acute myeloid leukemia].
    Wang ZZ, Lu Y, Xu YX, Xing HY, Tang KJ, Tian Z, Rao Q, Wang M, Xiong DS, Wang JX.
    Zhonghua Xue Ye Xue Za Zhi; 2020 Mar 14; 41(3):192-197. PubMed ID: 32311887
    [Abstract] [Full Text] [Related]

  • 31. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
    Christodoulou I, Ho WJ, Marple A, Ravich JW, Tam A, Rahnama R, Fearnow A, Rietberg C, Yanik S, Solomou EE, Varadhan R, Koldobskiy MA, Bonifant CL.
    J Immunother Cancer; 2021 Dec 14; 9(12):. PubMed ID: 34896980
    [Abstract] [Full Text] [Related]

  • 32. Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia.
    Wen J, Chen Y, Yang J, Dai C, Yu S, Zhong W, Liu L, He C, Zhang W, Yang T, Liu L, Hu J.
    J Immunother Cancer; 2023 Jul 14; 11(7):. PubMed ID: 37524506
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Chimeric antigen receptor T cell therapies for acute myeloid leukemia.
    Gu B, Chu J, Wu D.
    Front Med; 2020 Dec 14; 14(6):701-710. PubMed ID: 33263835
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123.
    Morgan MA, Kloos A, Lenz D, Kattre N, Nowak J, Bentele M, Keisker M, Dahlke J, Zimmermann K, Sauer M, Heuser M, Schambach A.
    Viruses; 2021 Jul 14; 13(7):. PubMed ID: 34372571
    [Abstract] [Full Text] [Related]

  • 37. B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia.
    Fan S, Wang T, You F, Zhang T, Li Y, Ji C, Han Z, Sheng B, Zhai X, An G, Meng H, Yang L.
    Eur J Med Res; 2023 Mar 20; 28(1):129. PubMed ID: 36941687
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.